Logo image of EXEL

EXELIXIS INC (EXEL) Stock Fundamental Analysis

NASDAQ:EXEL - US30161Q1040 - Common Stock

37.7 USD
-0.58 (-1.52%)
Last: 9/10/2025, 8:00:01 PM
37.98 USD
+0.28 (+0.74%)
After Hours: 9/10/2025, 8:00:01 PM
Fundamental Rating

8

Taking everything into account, EXEL scores 8 out of 10 in our fundamental rating. EXEL was compared to 541 industry peers in the Biotechnology industry. EXEL gets an excellent profitability rating and is at the same time showing great financial health properties. EXEL is growing strongly while it also seems undervalued. This is an interesting combination This makes EXEL very considerable for value and growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

EXEL had positive earnings in the past year.
EXEL had a positive operating cash flow in the past year.
EXEL had positive earnings in each of the past 5 years.
EXEL had a positive operating cash flow in each of the past 5 years.
EXEL Yearly Net Income VS EBIT VS OCF VS FCFEXEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

EXEL has a better Return On Assets (22.49%) than 97.04% of its industry peers.
EXEL has a Return On Equity of 29.62%. This is amongst the best in the industry. EXEL outperforms 97.23% of its industry peers.
Looking at the Return On Invested Capital, with a value of 25.22%, EXEL belongs to the top of the industry, outperforming 98.15% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for EXEL is significantly below the industry average of 15.95%.
The last Return On Invested Capital (25.22%) for EXEL is above the 3 year average (10.78%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROIC 25.22%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
EXEL Yearly ROA, ROE, ROICEXEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 150

1.3 Margins

With an excellent Profit Margin value of 27.01%, EXEL belongs to the best of the industry, outperforming 96.12% of the companies in the same industry.
EXEL's Profit Margin has declined in the last couple of years.
EXEL has a better Operating Margin (33.71%) than 97.78% of its industry peers.
EXEL's Operating Margin has declined in the last couple of years.
EXEL's Gross Margin of 96.59% is amongst the best of the industry. EXEL outperforms 95.75% of its industry peers.
EXEL's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
EXEL Yearly Profit, Operating, Gross MarginsEXEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), EXEL is creating value.
EXEL has less shares outstanding than it did 1 year ago.
The number of shares outstanding for EXEL has been reduced compared to 5 years ago.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EXEL Yearly Shares OutstandingEXEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EXEL Yearly Total Debt VS Total AssetsEXEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 11.47 indicates that EXEL is not in any danger for bankruptcy at the moment.
The Altman-Z score of EXEL (11.47) is better than 87.06% of its industry peers.
There is no outstanding debt for EXEL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 11.47
ROIC/WACC2.62
WACC9.62%
EXEL Yearly LT Debt VS Equity VS FCFEXEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

A Current Ratio of 3.51 indicates that EXEL has no problem at all paying its short term obligations.
With a Current ratio value of 3.51, EXEL perfoms like the industry average, outperforming 41.59% of the companies in the same industry.
EXEL has a Quick Ratio of 3.44. This indicates that EXEL is financially healthy and has no problem in meeting its short term obligations.
EXEL has a Quick ratio (3.44) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.51
Quick Ratio 3.44
EXEL Yearly Current Assets VS Current LiabilitesEXEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

8

3. Growth

3.1 Past

EXEL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 67.74%, which is quite impressive.
The Earnings Per Share has been growing by 12.65% on average over the past years. This is quite good.
EXEL shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.73%.
EXEL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 17.51% yearly.
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%

3.2 Future

EXEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.20% yearly.
Based on estimates for the next years, EXEL will show a quite strong growth in Revenue. The Revenue will grow by 10.31% on average per year.
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue Next Year7.29%
Revenue Next 2Y10.13%
Revenue Next 3Y11.67%
Revenue Next 5Y10.31%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EXEL Yearly Revenue VS EstimatesEXEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
EXEL Yearly EPS VS EstimatesEXEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 18.13, the valuation of EXEL can be described as rather expensive.
Based on the Price/Earnings ratio, EXEL is valued cheaper than 94.64% of the companies in the same industry.
EXEL's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.03.
Based on the Price/Forward Earnings ratio of 12.98, the valuation of EXEL can be described as correct.
EXEL's Price/Forward Earnings ratio is rather cheap when compared to the industry. EXEL is cheaper than 95.93% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.54, EXEL is valued a bit cheaper.
Industry RankSector Rank
PE 18.13
Fwd PE 12.98
EXEL Price Earnings VS Forward Price EarningsEXEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, EXEL is valued cheaply inside the industry as 95.93% of the companies are valued more expensively.
96.67% of the companies in the same industry are more expensive than EXEL, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.46
EV/EBITDA 11.17
EXEL Per share dataEXEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The excellent profitability rating of EXEL may justify a higher PE ratio.
A more expensive valuation may be justified as EXEL's earnings are expected to grow with 26.04% in the coming years.
PEG (NY)0.65
PEG (5Y)1.43
EPS Next 2Y25.29%
EPS Next 3Y26.04%

More info and screens

0

5. Dividend

5.1 Amount

EXEL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EXELIXIS INC

NASDAQ:EXEL (9/10/2025, 8:00:01 PM)

After market: 37.98 +0.28 (+0.74%)

37.7

-0.58 (-1.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-28 2025-07-28/amc
Earnings (Next)10-27 2025-10-27/amc
Inst Owners95.32%
Inst Owner Change-0.46%
Ins Owners2.23%
Ins Owner Change10.58%
Market Cap10.15B
Analysts77.69
Price Target45.9 (21.75%)
Short Float %6.42%
Short Ratio4.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)31.5%
Min EPS beat(2)13.99%
Max EPS beat(2)49.01%
EPS beat(4)4
Avg EPS beat(4)21.76%
Min EPS beat(4)10.66%
Max EPS beat(4)49.01%
EPS beat(8)6
Avg EPS beat(8)17.86%
EPS beat(12)9
Avg EPS beat(12)18.64%
EPS beat(16)12
Avg EPS beat(16)38.79%
Revenue beat(2)1
Avg Revenue beat(2)3.15%
Min Revenue beat(2)-3.02%
Max Revenue beat(2)9.31%
Revenue beat(4)2
Avg Revenue beat(4)3.21%
Min Revenue beat(4)-3.02%
Max Revenue beat(4)9.31%
Revenue beat(8)3
Avg Revenue beat(8)4.17%
Revenue beat(12)5
Avg Revenue beat(12)2.6%
Revenue beat(16)7
Avg Revenue beat(16)2.9%
PT rev (1m)-0.81%
PT rev (3m)10.04%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)4.31%
EPS NY rev (1m)0.62%
EPS NY rev (3m)4.33%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)1.61%
Revenue NY rev (1m)-0.59%
Revenue NY rev (3m)-0.25%
Valuation
Industry RankSector Rank
PE 18.13
Fwd PE 12.98
P/S 4.55
P/FCF 13.46
P/OCF 13.15
P/B 4.99
P/tB 5.15
EV/EBITDA 11.17
EPS(TTM)2.08
EY5.52%
EPS(NY)2.9
Fwd EY7.7%
FCF(TTM)2.8
FCFY7.43%
OCF(TTM)2.87
OCFY7.61%
SpS8.28
BVpS7.55
TBVpS7.32
PEG (NY)0.65
PEG (5Y)1.43
Profitability
Industry RankSector Rank
ROA 22.49%
ROE 29.62%
ROCE 32.1%
ROIC 25.22%
ROICexc 38.09%
ROICexgc 39.72%
OM 33.71%
PM (TTM) 27.01%
GM 96.59%
FCFM 33.81%
ROA(3y)10.23%
ROA(5y)8.95%
ROE(3y)13.24%
ROE(5y)11.23%
ROIC(3y)10.78%
ROIC(5y)9.34%
ROICexc(3y)19.16%
ROICexc(5y)19.43%
ROICexgc(3y)20.04%
ROICexgc(5y)20.66%
ROCE(3y)13.72%
ROCE(5y)11.89%
ROICexcg growth 3Y9.55%
ROICexcg growth 5Y2.44%
ROICexc growth 3Y10.88%
ROICexc growth 5Y3.03%
OM growth 3Y16.77%
OM growth 5Y-3.58%
PM growth 3Y14.28%
PM growth 5Y-6.24%
GM growth 3Y0.06%
GM growth 5Y-0.02%
F-Score8
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 60.32%
Cap/Sales 0.81%
Interest Coverage 250
Cash Conversion 98.79%
Profit Quality 125.2%
Current Ratio 3.51
Quick Ratio 3.44
Altman-Z 11.47
F-Score8
WACC9.62%
ROIC/WACC2.62
Cap/Depr(3y)129.54%
Cap/Depr(5y)238.73%
Cap/Sales(3y)1.75%
Cap/Sales(5y)2.56%
Profit Quality(3y)151.16%
Profit Quality(5y)151.8%
High Growth Momentum
Growth
EPS 1Y (TTM)67.74%
EPS 3Y37.61%
EPS 5Y12.65%
EPS Q2Q%-15.58%
EPS Next Y27.76%
EPS Next 2Y25.29%
EPS Next 3Y26.04%
EPS Next 5Y22.2%
Revenue 1Y (TTM)10.73%
Revenue growth 3Y14.76%
Revenue growth 5Y17.51%
Sales Q2Q%-10.82%
Revenue Next Year7.29%
Revenue Next 2Y10.13%
Revenue Next 3Y11.67%
Revenue Next 5Y10.31%
EBIT growth 1Y86.61%
EBIT growth 3Y34.01%
EBIT growth 5Y13.3%
EBIT Next Year42.25%
EBIT Next 3Y34.74%
EBIT Next 5Y1.16%
FCF growth 1Y108.65%
FCF growth 3Y25.89%
FCF growth 5Y5.48%
OCF growth 1Y98.36%
OCF growth 3Y20.43%
OCF growth 5Y5.84%